Friday’s trading has closed, but ABMD is being traded in the after-hours session.
After-Hours quote »| 21.98 Data as of 4:00pm ET |  +0.26 / +1.20%Today’s Change | 11.80 Today|||52-Week Range 24.93 | +63.54% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Medical Specialties | MARKET CAP $837.5M |
Company Description
ABIOMED, Inc. develops, manufactures and markets advanced medical technologies designed to assist or replace the pumping function of the failing heart. The company provides medical devices in circulatory support and offers a continuum of care in heart recovery to acute heart failure patients. It develops, manufactures and markets proprietary products that are designed to enable the heart to rest, heal and recover by improving blood flow and performing the pumping function of the heart. The company's products are used in the cardiac catheterization lab, or cath lab, by interventional cardiologists and in the heart surgery. It sells its products through clinical support personnel in the US, Canada, Germany, France, and the UK. ABIOMED was founded in 1981 and is headquartered in Danvers, MA.
Employees
Shareholders
| Mutual fund holders | 56.96% |
| Other institutional | 42.03% |
| Individual stakeholders | 21.79% |
Top Executives
| Michael R. Minogue, MBA | Chairman, President & Chief Executive Officer |
| David M. Weber, PhD | Chief Operating Officer |
| Robert L. Bowen, MBA | Chief Financial Officer, Treasurer & VP |
| Karim Benali, PhD | Chief Medical Officer |
| Thorsten Siess, PhD | Chief Technology Officer |
.
